Karen Pendergrass, Standards Team

This study reveals that intrauterine microbial colonization is prevalent in women with endometriosis, particularly with Streptococcaceae, Staphylococcaceae, and Enterobacteriaceae. Findings suggest that RHa treatment exacerbates microbial colonization, indicating a possible role for targeted antimicrobial therapies in managing endometriosis-associated inflammation.

The study identified distinct oral microbiome profiles in BS patients, particularly in those overweight, highlighting its potential as a non-invasive diagnostic tool for visceral pain severity and symptom progression.

This study identifies Parkinson’s disease gut microbiome signatures involving reduced CFAs and loss of key butyrate-producing taxa, highlighting microbial shifts that may influence enteric and neurological function.

Study showing gut microbiota and Parkinson’s disease are mechanistically linked through CFA-driven microglial activation, aSyn pathology, and motor impairment in mouse models and humanized microbiota experiments.

The study identifies significant fecal microbiota dysbiosis in BS patients, marked by increased Pseudomonas aeruginosa and Bacteroides thetaiotamicron, highlighting their potential as microbial biomarkers for BS subtypes.

This study identifies major gut microbiome alterations in Parkinson’s disease, especially reduced Prevotellaceae and increased Enterobacteriaceae linked to motor phenotype, suggesting clinically relevant microbial signatures.

This study identifies distinct dysbiosis in the colonic microbiota in Parkinson’s disease, marked by reduced butyrate-producing bacteria and increased proinflammatory taxa, suggesting microbial contributions to intestinal inflammation and alpha-synuclein pathology.

The study highlights functional dysbiosis in constipated-irritable bowel syndrome, with increased sulfate-reducing bacteria and disrupted CFA profiles.

The study investigated gut microbiota in diarrhea-predominant irritable bowel syndrome (BS), revealing distinct microbial shifts, including increased Enterobacteriaceae and reduced Faecalibacterium populations, indicating potential inflammatory mechanisms

The study identified significant shifts in fecal bile acid composition and gut microbiota in BS-D patients. Elevated primary bile acids and dysbiosis were linked to stool frequency and consistency, suggesting bile acid modulation as a potential therapeutic target for symptom management.

This study found that while probiotics may relieve BS symptoms, they do not revert the gut microbiota imbalances associated with the disorder.

This study reveals that diarrhea-predominant BS (BS) is linked to reduced microbial diversity and niche-specific dysbiosis in the gut.

This study identifies distinct microbiome signatures in pediatric BS, revealing unique microbial imbalances linked to disease subtypes.

This study identifies global microbiota signatures in BS patients, revealing distinct microbial imbalances that differentiate them from healthy controls. Key findings include a 2-fold increase in the Bacteroidetes ratio, reduced Bifidobacterium and Faecalibacterium populations, and significant shifts in methanogens. These alterations suggest potential diagnostic markers and therapeutic targets for BS.

This study reveals that altered microbiota and elevated organic acids in BS patients correlate with increased symptom severity, poorer quality of life, and heightened negative emotions. The findings suggest that microbial shifts leading to increased acetic and propionic acid production play a critical role in the pathophysiology of BS.

This study reveals that BS patients have significantly lower bifidobacteria counts in both fecal and duodenal samples compared to healthy controls. The marked reduction in Bifidobacterium catenulatum levels suggests a critical link to gut dysbiosis, impaired mucosal integrity, and potential contributions to symptom severity in BS subtypes.